Jaqueline Kraveka
Medical University of South Carolina
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jaqueline Kraveka as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:00 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05489887 · Naxitamab Added to Induction for Newly Diagnosed High-Risk NeuroblastomaGiselle Sholler · recruiting · Neuroblastoma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:00 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- SC COBRE: ROLE OF CERAMIDE IN HUMAN NEUROBLASTOMA DIFFERENTIATION AND TREATMENTP20RR017677 · NCRR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · fiscal years 2004 to 2007 · $68,722 awarded in 2007Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in neuroblastoma, ranked by citations from NIH iCite, fetched 2026-11-12 12:00 UTC. The ranking covers the 200 most relevant of 9 PubMed records, and a shared surname and initials can bring in a namesake. All 9 on PubMed
- 302 citationsRCR 11.9
- A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma.PLoS One · 2015125 citationsRCR 3.7
- 95 citationsRCR 3.4
- Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.J Clin Oncol · 202460 citationsRCR 7.9
- A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma.Int J Cancer · 202053 citationsRCR 2.6
- A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma.Pediatr Blood Cancer · 201626 citationsRCR 0.9
- A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma.Clin Cancer Res · 202216 citationsRCR 1.2
- Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial.Genome Med · 202412 citationsRCR 1.4
- A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma.Int J Cancer · 20239 citationsRCR 0.9